Trametinib Dimethyl Sulfoxide

Name: Trametinib Dimethyl Sulfoxide | 1187431-43-1
Brand: US-CATO
SKU: S57C1102872_10_MG
Price: 19998.0 USD
Availability: InStock

Cat. No S57C1102872_10_MG

Vendor: US-CATO

Product Information

Product Name

Trametinib Dimethyl Sulfoxide

Brand Name

US-CATO

Product Number

C1102872

CAS

1187431-43-1

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

50992434

IUPAC Name

N-3-3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido4,3-dpyrimidin-1-ylphenylacetamide;methylsulfinylmethane

InChI Key

OQUFJVRYDFIQBW-UHFFFAOYSA-N

SMILES

CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5.CS(=O)C

References Data Source From Pubchem

Perioperative Immunotherapy for Pancreatic Cancer: A Systematic Review of Randomized Controlled Trials

Publication Name: Journal of Gastrointestinal Cancer

Publication Date: 2026-03-03

DOI: 10.1007/s12029-026-01431-z

L1TD1 promotes colorectal mucinous adenocarcinoma progression by enhancing ABCC3 mRNA stability

Publication Name: Oncogene

Publication Date: 2026-03-03

DOI: 10.1038/s41388-026-03716-w

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer

Publication Name: International Journal of Clinical Oncology

Publication Date: 2026-02-28

DOI: 10.1007/s10147-026-02994-4

Dabrafenib/trametinib

Publication Name: Reactions Weekly

Publication Date: 2026-02-28

DOI: 10.1007/s40278-026-92771-z

Partial truncation of the C-terminal domain of PTCH1 in cancer promotes tumourigenesis by non-canonical activation of a GLI-PI3K loop

Publication Name: Oncogene

Publication Date: 2026-02-26

DOI: 10.1038/s41388-026-03698-9

Trametinib Dimethyl Sulfoxide

Product Information

General Information

References Data Source From Pubchem

Perioperative Immunotherapy for Pancreatic Cancer: A Systematic Review of Randomized Controlled Trials

L1TD1 promotes colorectal mucinous adenocarcinoma progression by enhancing ABCC3 mRNA stability

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer

Dabrafenib/trametinib

Partial truncation of the C-terminal domain of PTCH1 in cancer promotes tumourigenesis by non-canonical activation of a GLI-PI3K loop